Mark A. Meltz - 09 Jun 2025 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role: General Counsel
Signature: /s/ Charles Newton, as Attorney-in-Fact
Issuer symbol: LYEL
Transactions as of: 09 Jun 2025
Net transactions value: $0
Form type: 4
Filing time: 11 Jun 2025, 17:47:11 UTC
Previous filing: 05 Apr 2024
Next filing: 11 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Meltz Mark A	General Counsel	C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SUITE 101, SOUTH SAN FRANCISCO	/s/ Charles Newton, as Attorney-in-Fact	11 Jun 2025	0001771329

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LYEL	Option (right to buy)	Award	$0	+100,000		$0.000000	100,000	09 Jun 2025	Common Stock	100,000	$12.47	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	25% of the option shares will vest on June 9, 2026, with the remaining option shares to vest in equal monthly installments over the following thirty-six months, subject to the reporting person providing service through the applicable vesting date.